LIVN

AI MemoPost-earnings T+3

LivaNova

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

OSA launch milestones after aura6000 PMA approval • 2026-08-06

Base target: $81 / p=45% prob

Biggest risk

This is still a monitoring-style medtech thesis rather than a clean breakout. OSA remains early, reimbursement work is still ahead, and management’s own bridge shows some of the EPS uplift is offset by Middle East conflict-related costs. Delayed analyst target changes were not clearly available by T+3, so there is not yet strong external confirmation that the Street has materially lifted numbers beyond the company raise.

Invalidation

Break below $60 or thesis failure.

What would change my mind?

The strongest post-print read is straightforward: core franchises accelerated, guidance moved higher, and the company now has both a fresh FDA approval and a visible OSA launch roadmap. Secondary market-data sources indicated Q1 results were above pre-report consensus on both revenue and adjusted EPS, which supports a higher forward setup if estimate revisions follow.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-08

Base target

$81

p=45%

Bull target

$88

p=30%

Bear target

$60

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 beat-and-raise resets near-term expectations
Core device franchises are funding the next leg of growth
The strongest post-print read is straightforward: core franchises accelerated, guidance moved higher, and the company now has both a fresh FDA approval and a visible OSA launch roadmap.

BearKey bullets

Neuromodulation growth remained solid, but adjusted segment margin in that segment eased year over year, showing that not all operating leverage is flowing through cleanly [#8-K-2026-05-06].
OSA is still in an early launch phase; the earnings slides show a limited market release in H2 2026 and full market release in H1 2027, so commercialization and reimbursement execution remain open risks [#8-K-2026-05-06].
Q1 operating cash flow was $15.2M and adjusted free cash flow was $3.8M, so the company must improve materially through the year to reach its unchanged $160M-$180M adjusted free-cash-flow target [#8-K-2026-05-06].

WatchKey bullets

OSA launch milestones after aura6000 PMA approval

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $81 (p=45%)

Target spread vs base: +8% / -26%

Scenario probabilities

Bull Target: $88 (p=30%)Base Target: $81 (p=45%)Bear Target: $60 (p=25%)

Commentary

Primary-source tone improved after earnings. The company both raised 2026 guidance and highlighted aura6000 PMA approval, while LivaNova’s own IR stock-history page shows the stock moving from a May 5, 2026 close of $57.59 to $66.26 on May 6 and $70.92 on May 7, indicating a strong positive post-print reaction. Even so, delayed analyst target revisions were not clearly available by the T+3 follow-up window and the packet has no usable analyst-target-count field, so confidence should remain moderate rather than aggressive.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 beat-and-raise resets near-term expectations
Core device franchises are funding the next leg of growth

Scenarios

Bull Target (Scenario probability)

$88 / p=30% prob

Base Target (Scenario probability)

$81 / p=45% prob

Bear Target (Scenario probability)

$60 / p=25% prob

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.68

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
OSA launch milestones after aura6000 PMA approval
Management highlighted FDA PMA approval for the aura6000 System and showed upcoming OSA milestones including a limited market release in H2 2026 and full market release in H1 2027, creating a clearer path into the sleep-apnea category even though commercialization is still early [#8-K-2026-05-06].
Prob 65.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q1 beat-and-raise resets near-term expectations
2026-05-06
LivaNova reported Q1 2026 revenue of $362.3M, up 14.3% reported and 11.1% constant currency, with adjusted diluted EPS of $0.98, then raised full-year 2026 revenue growth guidance to 7.0%-8.0% and adjusted diluted EPS guidance to $4.20-$4.30 while maintaining adjusted free cash flow guidance at $160M-$180M [#8-K-2026-05-06].
Prob 80% • Move 9% • Priced-in 60%

Long-term Catalysts

Months to a year

Core device franchises are funding the next leg of growth
2026-12-31
Updated 2026 assumptions call for Cardiopulmonary revenue growth of 8.5%-9.5% and Epilepsy revenue growth of 6.0%-7.0%, supported by Essenz placements, consumables demand, implant growth, and price realization; if execution holds, the core business can finance OSA investment without breaking the margin and cash-flow framework [#8-K-2026-05-06].
Prob 70% • Move 10% • Priced-in 50%

Risks

Neuromodulation growth remained solid, but adjusted segment margin in that segment eased year over year, showing that not all operating leverage is flowing through cleanly [#8-K-2026-05-06].
OSA is still in an early launch phase; the earnings slides show a limited market release in H2 2026 and full market release in H1 2027, so commercialization and reimbursement execution remain open risks [#8-K-2026-05-06].
Q1 operating cash flow was $15.2M and adjusted free cash flow was $3.8M, so the company must improve materially through the year to reach its unchanged $160M-$180M adjusted free-cash-flow target [#8-K-2026-05-06].
The March 31, 2026 10-Q still shows a large SNIA environmental liability of about $389.5M, and the company defines a €270.0M first-demand bank guarantee tied to SNIA litigation, preserving a balance-sheet and legal overhang [#10-Q-2026-05-06].
The updated EPS bridge includes Middle East conflict impacts, and guidance still contemplates tariff and SNIA effects, limiting the quality of earnings conversion [#8-K-2026-05-06].

Peers

Symbol	Summary
BSX	Boston Scientific is a closer operating benchmark for hospital-facing medtech execution and new-therapy commercialization, though it has broader scale and a stronger portfolio than LIVN.
EW	Edwards Lifesciences is a useful premium-medtech valuation and regulatory-catalyst comparator, but its structural-heart mix is not a direct product match to LIVN’s cardiopulmonary, epilepsy, and OSA portfolio.
ABT	Abbott provides a broad device-scale benchmark for margins and hospital channel reach, but it is a loose peer given much wider diversification than LivaNova.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-08

Loading AI feed…

Symbol

Summary

BSX

Boston Scientific is a closer operating benchmark for hospital-facing medtech execution and new-therapy commercialization, though it has broader scale and a stronger portfolio than LIVN.

Edwards Lifesciences is a useful premium-medtech valuation and regulatory-catalyst comparator, but its structural-heart mix is not a direct product match to LIVN’s cardiopulmonary, epilepsy, and OSA portfolio.

ABT

Abbott provides a broad device-scale benchmark for margins and hospital channel reach, but it is a loose peer given much wider diversification than LivaNova.